CTX-130
CRISPR Therapeutics AG
[]
$crsp crispr therapeutics presents positive results from its phase 1 cobalt -lym trial of ctx130 in relapsed or refractory t cell malignancies at the 2022 european hematology association (eha) congress 
Free Stock Market News are delayed 15 sec. Full features and live news available here: https://t.co/fWRacb3Vft